U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Fluvoxamine response

MedGen UID:
808068
•Concept ID:
CN221254
•
Sign or Symptom
Synonym: Luvox response
Drug:
Fluvoxamine
MedGen UID:
88359
•Concept ID:
C0085228
•
Pharmacologic Substance
A 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and anxiolytic properties. Fluvoxamine, chemically unrelated to other selective serotonin reuptake inhibitors, selectively blocks serotonin reuptake by inhibiting the serotonin reuptake pump at the presynaptic neuronal membrane. This increases serotonin levels within the synaptic cleft, prolongs serotonergic transmission and decreased serotonin turnover, thereby leading to antidepressant, anxiolytic and antiobsessive-compulsive effects. Fluvoxamine shows no significant affinity for histaminergic, alpha or beta adrenergic, muscarinic, or dopaminergic receptors in vitro. [from NCI]
Fluvoxamine
 
Gene (location): CYP2D6 (22q13.2)

Definition

Serotonin reuptake inhibitor antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and serotonin modulators with SSRI-like properties are pharmacotherapy options for major depressive and anxiety disorders. Inadequate response and treatment-related adverse events are known challenges in antidepressant therapy. Genetic variations in genes encoding the drug metabolizing enzymes, CYP2D6, CYP2C19 and CYP2B6, have been shown to alter antidepressant biotransformation, which may potentially affect dosing, efficacy, and tolerability. [from PharmGKB]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  

Professional guidelines

PubMed

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR
Clin Pharmacol Ther 2023 Jul;114(1):51-68. Epub 2023 May 30 doi: 10.1002/cpt.2903. PMID: 37032427Free PMC Article
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR
Lancet 2018 Apr 7;391(10128):1357-1366. Epub 2018 Feb 21 doi: 10.1016/S0140-6736(17)32802-7. PMID: 29477251Free PMC Article
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA
J Affect Disord 2015 Jul 15;180:179-84. Epub 2015 Mar 31 doi: 10.1016/j.jad.2015.03.021. PMID: 25911132

Curated

CPIC® Guideline for Serotonin Reuptake Inhibitor Antidepressants and CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A, 2023

Recent clinical studies

Etiology

Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S
Int Clin Psychopharmacol 2014 Nov;29(6):344-50. doi: 10.1097/YIC.0000000000000043. PMID: 24850229
Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
Kishi T, Kitajima T, Ikeda M, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Ozaki N, Iwata N
Neuropsychobiology 2009;59(4):234-8. Epub 2009 Jul 2 doi: 10.1159/000226612. PMID: 19571598
Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.
Tsunoka T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Inada T, Ozaki N, Iwata N
Prog Neuropsychopharmacol Biol Psychiatry 2009 Aug 1;33(5):875-9. Epub 2009 Apr 19 doi: 10.1016/j.pnpbp.2009.04.007. PMID: 19386277
Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study.
Walkup J, Labellarte M, Riddle MA, Pine DS, Greenhill L, Fairbanks J, Klein R, Davies M, Sweeney M, Abikoff H, Hack S, Klee B, Bergman RL, Lynn D, McCracken J, March J, Gammon P, Vitiello B, Ritz L, Roper M; Research Units on Pediatric Psychopharmacology Anxiety Study Group
J Child Adolesc Psychopharmacol 2002 Fall;12(3):175-88. doi: 10.1089/104454602760386879. PMID: 12427292
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L
Pharmacogenomics J 2002;2(3):176-81. doi: 10.1038/sj.tpj.6500090. PMID: 12082589

Diagnosis

Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S
Int Clin Psychopharmacol 2014 Nov;29(6):344-50. doi: 10.1097/YIC.0000000000000043. PMID: 24850229
Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H, Sato K, Yoshida K, Takahashi H, Kamata M, Otani K, Yamaguchi N
Psychiatry Clin Neurosci 2008 Jun;62(3):301-6. doi: 10.1111/j.1440-1819.2008.01797.x. PMID: 18588590
Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder.
Neziroglu F, Pinto A, Yaryura-Tobias JA, McKay D
Psychiatry Res 2004 Jan 30;125(1):53-60. doi: 10.1016/j.psychres.2003.10.001. PMID: 14967552
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.
Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L
Pharmacogenomics J 2002;2(3):176-81. doi: 10.1038/sj.tpj.6500090. PMID: 12082589
Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA
J Clin Psychiatry 2001 Feb;62(2):87-91. doi: 10.4088/jcp.v62n0203. PMID: 11247107Free PMC Article

Therapy

Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder.
Okuda A, Suzuki T, Kishi T, Yamanouchi Y, Umeda K, Haitoh H, Hashimoto S, Ozaki N, Iwata N
Psychiatry Clin Neurosci 2010 Jun;64(3):268-73. doi: 10.1111/j.1440-1819.2010.02091.x. PMID: 20602727
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
Okumura T, Kishi T, Okochi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Tsunoka T, Inada T, Ozaki N, Iwata N
Neuropsychobiology 2010;61(2):57-63. Epub 2009 Dec 12 doi: 10.1159/000265130. PMID: 20016223
Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.
Tsunoka T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Inada T, Ozaki N, Iwata N
Prog Neuropsychopharmacol Biol Psychiatry 2009 Aug 1;33(5):875-9. Epub 2009 Apr 19 doi: 10.1016/j.pnpbp.2009.04.007. PMID: 19386277
Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H, Sato K, Yoshida K, Takahashi H, Kamata M, Otani K, Yamaguchi N
Psychiatry Clin Neurosci 2008 Jun;62(3):301-6. doi: 10.1111/j.1440-1819.2008.01797.x. PMID: 18588590
Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA
J Clin Psychiatry 2001 Feb;62(2):87-91. doi: 10.4088/jcp.v62n0203. PMID: 11247107Free PMC Article

Prognosis

Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H, Sato K, Yoshida K, Takahashi H, Kamata M, Otani K, Yamaguchi N
Psychiatry Clin Neurosci 2008 Jun;62(3):301-6. doi: 10.1111/j.1440-1819.2008.01797.x. PMID: 18588590
Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder.
Neziroglu F, Pinto A, Yaryura-Tobias JA, McKay D
Psychiatry Res 2004 Jan 30;125(1):53-60. doi: 10.1016/j.psychres.2003.10.001. PMID: 14967552
Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study.
Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA
Neuropsychopharmacology 2002 Nov;27(5):782-91. doi: 10.1016/S0893-133X(02)00351-2. PMID: 12431852
Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K
Neuropsychobiology 2002;46(3):136-40. doi: 10.1159/000066394. PMID: 12422060
Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA
J Clin Psychiatry 2001 Feb;62(2):87-91. doi: 10.4088/jcp.v62n0203. PMID: 11247107Free PMC Article

Clinical prediction guides

Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder.
Okuda A, Suzuki T, Kishi T, Yamanouchi Y, Umeda K, Haitoh H, Hashimoto S, Ozaki N, Iwata N
Psychiatry Clin Neurosci 2010 Jun;64(3):268-73. doi: 10.1111/j.1440-1819.2010.02091.x. PMID: 20602727
Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
Okumura T, Kishi T, Okochi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Tsunoka T, Inada T, Ozaki N, Iwata N
Neuropsychobiology 2010;61(2):57-63. Epub 2009 Dec 12 doi: 10.1159/000265130. PMID: 20016223
Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.
Tsunoka T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y, Kinoshita Y, Kawashima K, Okochi T, Okumura T, Inada T, Ozaki N, Iwata N
Prog Neuropsychopharmacol Biol Psychiatry 2009 Aug 1;33(5):875-9. Epub 2009 Apr 19 doi: 10.1016/j.pnpbp.2009.04.007. PMID: 19386277
Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H, Sato K, Yoshida K, Takahashi H, Kamata M, Otani K, Yamaguchi N
Psychiatry Clin Neurosci 2008 Jun;62(3):301-6. doi: 10.1111/j.1440-1819.2008.01797.x. PMID: 18588590
Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA
J Clin Psychiatry 2001 Feb;62(2):87-91. doi: 10.4088/jcp.v62n0203. PMID: 11247107Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • CPIC, 2023
      CPIC® Guideline for Serotonin Reuptake Inhibitor Antidepressants and CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A, 2023

    Consumer resources

    Reviews

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...